Oscar Health
OSCR
$30.05
-3.81%
Oscar Health, Inc. is a healthcare technology company that operates as a full-stack insurance carrier, offering Individual & Family plans and health technology solutions through federal and state-run ACA exchanges. It distinguishes itself as a tech-forward, member-centric insurer leveraging a proprietary platform to streamline care delivery and reduce costs. The current investor narrative centers on Oscar's dramatic turnaround from persistent losses to a profitable trajectory, highlighted by its first-quarter 2026 net income of $679 million and a 52.5% year-over-year revenue surge, which has fueled a 107.8% stock price rally over the past year. The market is debating whether this growth is sustainable and whether the stock's valuation adequately reflects its improving fundamentals.…
OSCR
Oscar Health
$30.05
Related headlines
Investment Opinion: Should I buy OSCR Today?
Based on the analysis, Oscar Health is rated a Hold. The stock's explosive growth and recent profitability are offset by high valuation and analyst skepticism, with a consensus Hold rating and an average target of $30.40, implying a -5.1% downside from the current price of $32.04. The thesis is that while the company has made significant progress, the current price already reflects much of the optimism, leaving limited upside without flawless execution.
Sign up to view all
OSCR 12-Month Price Forecast
The AI assessment is neutral, reflecting a balanced view of Oscar's strong growth and profitability against its high valuation and volatility. The stock's forward P/E is attractive if growth continues, but the consensus Hold rating and target price below current levels suggest limited upside. Key factors to watch include sustained revenue growth, margin stability, and regulatory developments. An upgrade to bullish would require evidence of durable profitability and continued growth, while a downgrade to bearish would be triggered by a significant slowdown or adverse policy changes.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Oscar Health's 12-month outlook, with a consensus price target around $30.40 and implied upside of +1.2% versus the current price.
Average Target
$30.40
0 analysts
Implied Upside
+1.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$25 - $39
Analyst target range
The target price range is $25.00 (low) to $39.00 (high), with an average of $30.40. The high target of $39.00 implies a 21.7% upside from the current price, suggesting that some analysts see significant potential if the company continues to execute on its growth and profitability goals. The low target of $25.00 implies a -22.0% downside, reflecting concerns about competitive pressures, regulatory changes, or a potential slowdown in growth. The wide spread between the low and high targets (56% difference from the average) indicates high uncertainty about the company's future performance. Recent institutional ratings show a mix of upgrades and downgrades, with Barclays upgrading to Overweight in June 2026, while Wells Fargo maintains an Underweight rating, indicating divergent views among analysts. This wide dispersion in targets and ratings suggests that the stock is subject to significant debate, and investors should be prepared for volatility.
Bulls vs Bears: OSCR Investment Factors
Oscar Health presents a compelling bull case driven by explosive revenue growth, a historic profitability milestone, and attractive forward valuation metrics. However, the bear case highlights elevated valuation risk, extreme volatility, and analyst skepticism, with a consensus Hold rating and a target price below the current level. The most critical tension lies in whether the company can sustain its growth and profitability trajectory to justify the current valuation. If Oscar continues to deliver strong earnings, the stock could rally further, but any stumble could trigger a sharp correction given the high expectations embedded in the price.
Bullish
- Explosive Revenue Growth: Q1 2026 revenue surged 52.5% YoY to $4.65B, up from $3.05B in Q1 2025, with accelerating growth across recent quarters. This top-line momentum is a core driver of the investment thesis, showcasing the company's ability to scale its insurance business.
- First-Ever Quarterly Net Income: Oscar reported a record net income of $679M in Q1 2026, a dramatic turnaround from losses in prior quarters. This profitability milestone validates the company's path to sustainable earnings and has fueled the stock's 107.8% rally over the past year.
- Strong Forward Valuation: With a forward P/E of 17.03 and a PEG ratio of 0.0052, the stock appears undervalued relative to its expected earnings growth. The market is pricing in significant future profitability, which could lead to further upside if the company delivers.
- Exceptional Relative Strength: The stock has outperformed the S&P 500 by 87.3 percentage points over the past year, with a 1-year return of 107.8% vs. the index's 20.5%. This momentum reflects strong investor confidence and a positive market perception of the company's turnaround.
Bearish
- High Valuation Risk: Despite the forward P/E of 17.03, the trailing P/E is -8.50, and the stock trades at 95.7% of its 52-week range. If earnings growth disappoints, the stock could face significant multiple compression, given the market's high expectations.
- Extreme Beta and Volatility: With a beta of 2.385, the stock is highly sensitive to market swings, amplifying both gains and losses. The max drawdown of -51.71% over the past year highlights the potential for severe downside in adverse conditions.
- Analyst Skepticism: The consensus rating is 'Hold' with an average target of $30.40, implying a -5.1% downside from the current price of $32.04. The low target of $25.00 suggests a -22.0% potential decline, reflecting concerns about sustainability of growth.
- Dependence on ACA Market: Oscar's business is heavily reliant on ACA exchanges, making it vulnerable to regulatory changes and policy shifts. Any adverse modifications to the ACA could directly impact membership and revenue, posing a significant risk.
OSCR Technical Analysis
Oscar Health has been in a powerful sustained uptrend over the past year, with the stock price surging 107.8% from a 52-week low of $10.69 to a recent close of $32.04. The current price sits at 95.7% of its 52-week range (calculated as (32.04 - 10.69) / (33.48 - 10.69)), indicating the stock is trading near its highs, which typically signals strong momentum but also potential overextension. The 1-year price change of 107.8% vastly outperforms the S&P 500's 20.5% gain, demonstrating exceptional relative strength (relative strength of 87.3 over 1 year). This positioning suggests the market is rewarding the company's fundamental improvements, but investors should be cautious of a potential pullback given the extended nature of the move.
Beta
2.38
2.38x market volatility
Max Drawdown
-51.7%
Largest decline past year
52-Week Range
$11-$34
Price range past year
Annual Return
+76.6%
Cumulative gain past year
| Period | OSCR Return | S&P 500 |
|---|---|---|
| 1m | -4.3% | +4.1% |
| 3m | +35.2% | +1.9% |
| 6m | +120.3% | +12.4% |
| 1y | +76.6% | +19.3% |
| ytd | +100.7% | +13.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OSCR Fundamental Analysis
Oscar Health's revenue trajectory has been robust, with the most recent quarter (Q1 2026) reporting revenue of $4.65 billion, a 52.5% year-over-year increase from $3.05 billion in Q1 2025. This growth is accelerating, as the prior four quarters showed revenues of $2.81 billion (Q4 2025), $2.99 billion (Q3 2025), $2.86 billion (Q2 2025), and $3.05 billion (Q1 2025), indicating a clear upward trend. The company's top-line expansion is driven by strong member growth and premium increases, though segment data is not available. This accelerating growth is a key pillar of the investment thesis, as it demonstrates the company's ability to scale its insurance business effectively.
Quarterly Revenue
$4.6B
2026-03
Revenue YoY Growth
+52.5%
YoY Comparison
Gross Margin
30.5%
Latest Quarter
Free Cash Flow
$2.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OSCR Overvalued?
Given that Oscar Health reported a net income of $679 million in Q1 2026, the trailing twelve-month net income is positive, so I selected the P/E ratio as the primary valuation metric. The trailing P/E is -8.50, which is not meaningful due to the company's historical losses, but the forward P/E is 17.03, implying the market expects significant earnings growth. The gap between the negative trailing and positive forward P/E reflects the market's anticipation of sustained profitability, which is a positive signal if the company can deliver. The PEG ratio of 0.0052 is extremely low, suggesting the stock is undervalued relative to its expected earnings growth, though this metric should be interpreted with caution given the company's volatile earnings history.
PE
-8.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~5x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-3.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Oscar Health has demonstrated a dramatic turnaround, but risks remain. The company's debt-to-equity ratio of 0.44 is manageable, yet its current ratio of 0.95 indicates potential liquidity concerns. The negative operating margin of -3.39% and net margin of -3.79% over the trailing twelve months highlight that profitability is not yet consistent, despite the strong Q1 2026 net income. Revenue concentration in the ACA market adds vulnerability to policy changes, and the company's reliance on continued growth to justify its valuation is a key risk. If growth decelerates, the stock could face significant downside, as evidenced by the 52-week low of $10.69, which is 66.6% below the current price.
FAQ
The key risks for Oscar Health include: 1) Financial risk: high volatility with a beta of 2.385 and a max drawdown of -51.71%, indicating potential for large losses. 2) Competitive risk: intense competition in the ACA marketplace from larger insurers like UnitedHealth and Humana. 3) Regulatory risk: dependence on ACA policies, which could change with new legislation. 4) Execution risk: the company's profitability is recent and may not be sustainable, as evidenced by negative operating margins over the trailing twelve months. The most severe risk is a combination of these factors leading to a decline toward the 52-week low of $10.69, a -66.6% drop from the current price.
The 12-month forecast for Oscar Health is mixed. The bull case, with a 30% probability, targets $35-$39, driven by sustained growth and profitability. The base case, with a 45% probability, targets $28-$32, aligning with the analyst average of $30.40. The bear case, with a 25% probability, targets $20-$25, if growth slows or regulatory issues arise. The most likely scenario is the base case, assuming the company maintains its growth trajectory but faces some headwinds. Investors should monitor quarterly earnings for signs of growth deceleration.
Oscar Health's valuation is a mixed picture. The forward P/E of 17.03 is reasonable for a company with 52.5% revenue growth, and the PEG ratio of 0.0052 suggests undervaluation relative to growth. However, the trailing P/E is negative, and the stock trades at 95.7% of its 52-week range, indicating high expectations. Compared to peers, the P/S ratio of 0.32 is low, but the EV/Sales of 0.11 is even lower, suggesting the market is pricing in significant future growth. Overall, the stock is fairly valued if growth continues, but overvalued if growth decelerates.
Oscar Health presents a compelling growth story with 52.5% YoY revenue growth and a historic Q1 2026 net income of $679M, but the stock trades at a premium with a forward P/E of 17.03 and a consensus Hold rating. The average analyst target of $30.40 implies a -5.1% downside from the current price, suggesting limited upside in the near term. For risk-tolerant investors with a long-term perspective, the stock could be a good buy if growth persists, but it is not suitable for conservative investors. The biggest risk is a slowdown in growth or regulatory changes, which could lead to a significant decline toward the 52-week low of $10.69.
Oscar Health is better suited for long-term investment, given its high beta of 2.385 and significant volatility. The company is in a growth phase, with revenue expanding 52.5% YoY, but its earnings history is volatile, with recent profitability only in Q1 2026. Short-term trading could be profitable due to momentum, but the risk of sharp pullbacks is high. For long-term investors, a minimum holding period of 3-5 years is recommended to allow the company to mature and demonstrate consistent profitability. The stock's low P/S ratio of 0.32 suggests potential for long-term appreciation if growth continues.